Replies to post #42618 on Biotech Values

[jellybean]

ITMN-191 was developed by Array Biopharma. They specifically designed the drug to remove the cardiotoxicity that was observed in the BILN drug.

[DewDiligence]

>Given that InterMune has publicly stated they have a preclinical HCV target (outside of the Protease Roche collaboration) there is a decent chance InterMune has their own preclinical Polymerase. I guess a Helix Inhibitor is a decent possibility as well.<

Do you mean a helicase inhibitor?